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Long-term opioid treatment results in reduced therapeutic efficacy and in turn leads to an
increase in the dose required to produce equivalent pain relief and alleviate break-through
or insurmountable pain. Altered gene expression is a likely means for inducing long-term
neuroadaptations responsible for tolerance. Studies conducted by our laboratory
(Tapocik et al., 2009) revealed a network of gene expression changes occurring in
canonical pathways involved in neuroplasticity, and uncovered miRNA processing as
a potential mechanism. In particular, the mRNA coding the protein responsible for
processing miRNAs, Dicer1, was positively correlated with the development of analgesic
tolerance. The purpose of the present study was to test the hypothesis that miRNAs
play a significant role in the development of analgesic tolerance as measured by thermal
nociception. Dicer1 knockdown, miRNA profiling, bioinformatics, and confirmation of
high value targets were used to test the proposition. Regionally targeted Dicer1
knockdown (via shRNA) had the anticipated consequence of eliminating the development
of tolerance in C57BL/6J (B6) mice, thus supporting the involvement of miRNAs in
the development of tolerance. MiRNA expression profiling identified a core set of
chronic morphine-regulated miRNAs (miR’s 27a, 9, 483, 505, 146b, 202). Bioinformatics
approaches were implemented to identify and prioritize their predicted target mRNAs.
We focused our attention on miR27a and its predicted target serpin peptidase inhibitor
clade I (Serpini1) mRNA, a transcript known to be intricately involved in dendritic spine
density regulation in a manner consistent with chronic morphine’s consequences and
previously found to be correlated with the development of analgesic tolerance. In vitro
reporter assay confirmed the targeting of the Serpini1 3′-untranslated region by miR27a.
Interestingly miR27a was found to positively regulate Serpini1mRNA and protein levels in
multiple neuronal cell lines. Lastly, Serpini1 knockout mice developed analgesic tolerance
at a slower rate than wild-type mice thus confirming a role for the protein in analgesic
tolerance. Overall, these results provide evidence to support a specific role for miR27a
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and Serpini1 in the behavioral response to chronic opioid administration (COA) and
suggest that miRNA expression and mRNA targeting may underlie the neuroadaptations
that mediate tolerance to the analgesic effects of morphine.
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INTRODUCTION
Opioid analgesics are the foundational treatment in pain
management. No other drug provides better relief from the
sensory and affective components of pain. Unfortunately, long-
term opioid treatment results in reduced therapeutic efficacy and
in turn leads to an increase in the dose required to produce
equivalent pain relief, break-through, or insurmountable pain
(Carroll et al., 2004; Angst and Clark, 2006; Colameco et al.,
2009; Fishbain et al., 2009; Silverman, 2009; Zernikow et al.,
2009; Bekhit, 2010; Crofford, 2010), increased adverse side-effects
(Mercadante, 1999; Mercadante and Portenoy, 2001) and may
progress to opioid dependence and addiction (Banta-Green et al.,
2009; Shurman et al., 2010). Despite the clinical importance of
diminishing the development of analgesic tolerance and decades
of research into the neurobiological consequences of chronic
opioid administration (COA), the mechanism is still poorly
understood and only limited intervention strategies are available
(Huxtable et al., 2011; Labianca et al., 2012).
The subjective experience of pain and its alleviation by opioids
involve direct sensory perception and cognitive and affective
response (Price, 2000; Rainville, 2002). The direct, affective
and cognitive/associative components of pain and analgesia are
mediated throughout central nervous system (CNS) regions
containing µ-opiate receptors including periaqueductal gray,
amygdala, lateral habenula, dorsal raphe, anterior cingulate,
and prefrontal cortex (PFC) (Pastoriza et al., 1996; Wagner
et al., 2001; Craggs et al., 2007; Wager et al., 2007; Petrovic
et al., 2010; Stockton and Devi, 2014; Zeidan et al., 2015).
A clear consensus on specific canonical pathways altered by
COA has not been reached, however complex intracellular
neuroadaptations in direct response to opioid administration
(Chu et al., 2008; Drdla et al., 2009; Ueda and Ueda, 2009;
Abul-Husn et al., 2011; Ziolkowska et al., 2012; Williams et al.,
2013) initiate complex synaptic reorganization characterized by
altered neurotransmission (Abul-Husn et al., 2011) and synaptic
architecture (Russo et al., 2010; Abul-Husn et al., 2011; Stockton
and Devi, 2014) such as decreased spine density (Robinson et al.,
2002), cytoskeletal structure (Hou et al., 2009; Li et al., 2009), cell
size (Russo et al., 2007), and neurotransmitter relevant protein
distribution (Xu et al., 2003; Mickiewicz and Napier, 2011).
Neuroadaptations initiated by COA are additionally contingent
upon context-dependent associative components (Tiffany et al.,
1991; Cox and Tiffany, 1997; Mitchell et al., 2000; Miguez et al.,
2014) that together underlie the behavioral effects of repeated
opioid administration. At a genomics level, recent studies in our
laboratories anchored morphine-induced region-specific mRNA
expression patterns to specific behavioral endpoints such as
analgesic tolerance (Tapocik et al., 2009) and morphine self-
administration (Tapocik et al., 2013) in order to improve the
likelihood of identifying causal genes (Letwin et al., 2006; Reiner-
Benaim et al., 2007; Tapocik et al., 2009). Bioinformatics analysis
of these data sets revealed a statistical over-representation of gene
expression changes occurring in canonical pathways responsible
for regulating neuroplasticity and the processing of miRNAs.
Given the significant amount of support for neuroplasticity
changes following COA (Kauer and Malenka, 2007; Kalivas
and O’Brien, 2008; McClung and Nestler, 2008; Stockton and
Devi, 2014), altered miRNA expression is a promising candidate
to coordinate the complex response. MiRNAs are a class of
noncoding RNAs that regulate gene expression by targeting
mRNAs for translation inhibition and/or mRNA degradation
(He and Hannon, 2004). These molecules are thought to
regulate as much as one-third of the transcribed genome
(Stefani and Slack, 2008) and can mediate short and long
term neuroplasticity including structural regulation by sculpting
dendritic architecture (Kosik, 2006; Schratt et al., 2006; Wayman
et al., 2008). A recent series of promising studies specifically
confirmed a role for the miRNA let-7 in the development of
analgesic tolerance following high opioid doses (He et al., 2010;
He and Wang, 2012) and several other miRNAs following opioid
administration (miR-103/miR-107, -124, 190, -23b, -133b, -339)
(Wu et al., 2009, 2013; Sanchez-Simon et al., 2010; Zheng et al.,
2010a,c; Ni et al., 2013; Gonzalez-Nunez et al., 2014; Lu et al.,
2014; Qiu et al., 2015). Despite the strategic capacity of miRNAs
to mediate dynamic and long-term neuroplasticity, surprisingly
few studies have determined their global differential regulation
following administration of chronic opioids (Wu et al., 2008,
2009, 2013; Dave and Khalili, 2010; Zheng et al., 2010c; Gonzalez-
Nunez et al., 2014; Tang et al., 2014).
Based upon our discovery that Dicer1, the rate limiting
enzyme in miRNA production (Kosik and Krichevsky, 2005),
was positively associated with the development of tolerance
(Tapocik et al., 2009) and the suggested miRNA involvement
in morphine self-administration (Tapocik et al., 2013), we
hypothesized that COA alters miRNA expression profiles
in a manner that modulates relevant neuroplasticity mRNA
expression. Several experimental conditions and genotypes were
exposed to repeated administration of therapeutically relevant
morphine doses to assess the altered tolerance development in a
thermal nociception assay. ShRNA-mediated Dicer1 knockdown
and genotypes that are sensitive and resistant to the development
of tolerance (C57BL/6J and DBA/2J, respectively) were utilized
to provide evidence to support a significant role for miRNA
processing in analgesic tolerance. Regional miRNA expression
profiling following COA in the C57BL/6J mice and refinement
by comparison to tolerance-insensitive DBA/2J mice led to
the identification of intriguing synaptic organization miRNA
candidates and the identification of a unique miRNA-mRNA-
protein axis putatively involved in synaptic organization.
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MATERIALS AND METHODS
Animals
Adult male C57BL/6J (B6), DBA/2J (D2), and B6.129-
Serpini1tm1Dpw/J (Serpini1 KO) mice (Jackson Laboratories,
Bar Harbor, ME), 60–120 days old and weighing ∼21–28 g at
the start of the experiment were used. Only males were tested in
order to permit miRNA-mRNA pairing analysis by combining
our previous mRNA data set obtained in males (Tapocik et al.,
2009) with our current miRNA analysis (see below). All animals
were experimentally naive, housed in a temperature-controlled
room (21◦C; 0700–1900 lights on), and given free access to
chow and tap water during the entire experimental procedure.
The treatment of animals followed the Principles of Laboratory
Animal Care (NIH publication no.86-23, 1996) and was
approved by the Institutional Animal Care and Use Committee
of the University of Maryland School of Medicine.
Analgesic Tolerance Assessment (General
Description)
The ability of a high, therapeutically relevant dose of morphine to
maintain analgesic efficacy across three spaced administrations
(48 h) was used as the endpoint for tolerance. The specific
morphine dose for each condition and genotype tested are given
in each respective section. Saline vehicle controls accounted
for any potential group differences across repeated exposure to
the hot-plate testing and were utilized in the calculation for
percent maximal possible effect (%MPE) (see analysis below).
Morphine-induced analgesic effects were determined on a hot-
plate maintained at a constant temperature of 55◦C. The subject
was placed on the hot- plate 15 min post sub-cutaneous (s.c.)
saline or morphine (Sigma-Aldrich, St Louis, MO) injection (0.01
ml/kg). A large 25 cm diameter circular plastic container served
to restrict mice to the hot-plate. Saline or the ED90 dose of
morphine was administered between the hours of 8:00–11:00 a.m.
The dependent measure used to assess thermal antinociception
was the latency to paw lick (hind or front). A cut-off time of
four times each genotype’s saline control value was used to avoid
tissue damage and to factor in important genotype-dependent
differences in baseline nociception (Elmer et al., 1998). The
analgesic tests are described in the order they were conducted.
Data were analyzed as the %MPE. The saline vehicle group for
each respective genotype was used as the baseline latency in the
following formula:
100∗
[((
test latency
)
−
(
saline baseline latency
))
((
4∗baselinelatency
)
−
(
baselinelatency
))
]
Analgesic experiments were analyzed using two-way repeated
measures ANOVA (genotype× injection number) and co-varied
for treatment order within a cage.
Lentiviral shRNA Dicer
Four experimental groups of B6 mice were used in this
experiment: Nonsense shRNA-morphine, Nonsense shRNA-
saline, Dicer1 shRNA-morphine, Dicer1 shRNA-saline (n = 6, 7,
6, and 6, respectively). Four weeks following nonsense shRNA or
Dicer1 shRNA injection into the PFC (see full virus preparation
and surgery description below), mice were administered 31.2
mg/kg morphine (s.c.) or saline (s.c.) once every other day over
a 5-day period (total 3 treatments) and assessed for tolerance
by the hot plate test following the last treatment. The morphine
dose represents the ED90 in B6 mice (see below). Saline or
the morphine was administered s.c. between the hours of 8:00–
11:00 a.m. Brains were harvested for immunohistochemistry
confirmation following the last treatment.
B6 and D2 Mice
Analgesic tolerance was assessed in four groups of mice; B6
saline control, B6 morphine, D2 saline control, D2 morphine
(Total N = 10, 10, 9, and 8, respectively). Following assessment
of analgesic tolerance, brain tissue was harvested for miRNA
expression profiling (B6; n = 4 each for saline and morphine
treatment) or rtPCR confirmation of candidate miRNAs (B6;
n= 6 each for saline andmorphine treatment) and determination
of candidate miRNA expression levels in tolerant-resistant mice
(D2; n = 4 each for saline and morphine treatment). As stated
previously, saline controls accounted for any potential differences
across repeated exposure to the hot-plate testing and were
utilized in the calculation for percent maximal possible effect
(%MPE) (see analysis below). The dose of morphine required
to produce ∼90% of the %MPE for B6 and D2 was used
to induce tolerance since tolerance to the analgesic effects of
morphine develops at a rate directly related to the magnitude
of the initial pharmacological effect (Cox and Tiffany, 1997).
If the same dose of morphine was used to induce tolerance in
subjects that differ significantly in the acute analgesic potency
of morphine, tolerance could appear to develop more rapidly
in sensitive genotypes given the greater magnitude of the initial
pharmacological effect. This confound would affect the tolerance
outcome and interpretation. Thus, the experiment accounts for
this by using genotype-specific doses within a “therapeutic”
range, (ED90). The ED90 dose of morphine for the B6 and D2
mice was 31.2 and 7.7 mg/kg, respectively, as determined by full
dose-effect curve analysis in a previous experiment (see Figure 1
of Tapocik et al., 2009). Mice were administered 31.2 mg/kg
morphine (s.c.) or saline (s.c.) once every other day over a 5-day
period (total 3 treatments) and assessed for tolerance by the hot
plate test after each treatment.
Serpini1 KO
Four groups of mice were tested in this experiment; Serpini1
KO saline control, Serpini1 KO morphine, B6 saline control, B6
morphine (n = 8, 8, 6, and 6, respectively) as described above.
For the experiments using Serpini1KOmice the B6mouse served
as the WT control (per Jackson Laboratory recommendation).
While the ED90 dose for B6 mice is 31.2 mg/kg (see above), a
slightly higher dose (42.0 mg/kg) was used for these resource
intensive KO and B6 controls in order to ensure full tolerance
following three drug administrations.
Lentiviral Delivery of shRNA Targeting
Dicer1
We had previously demonstrated that Dicer1 expression in the
PFC was positively correlated with the development of analgesic
tolerance across a panel of inbred mouse strains (Tapocik
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et al., 2009). B6 mice, a strain exhibiting the highest levels of
Dicer1 mRNA, displayed the greatest tolerance following COA.
Conversely, the D2 strain had the lowest levels of Dicer1 and
exhibited the least tolerance. Consequently, the effects of Dicer1
knockdown on analgesic tolerance were investigated.
Lentiviral production and shRNA vector construction
were performed as previously described (Riz et al.,
2010) with the following modifications. shRNA design
was accomplished using a selection program available at
http://jura.wi.mit.edu/bioc/siRNAext/. Dicer1 shRNA targeting
sequence 5′CGCCGATCTCTAATTACGTAATAGTGAAGC
CACAGATGTA TTACGTAATTAGAGATCGGCG-3′ or
nonsense sequence 5′CCAAATTATACCTAC ATTGCTTAG
TGAAGCCACAGATGTAAGCAATGTAGGTATAATTTGG-3′
was cloned into the shuttle vector pENTR for recombination with
the pLenti6.2 destination vector containing green fluorescent
protein (GFP) (Gateway Technology, Life Technologies,
Grand Island, NY). A BLAST search on shRNA sequences
was performed against the mouse RefSeq database to ensure
target specificity. The destination plasmid pLenti6.2 with
shRNA targeting sequence, VSV-G protein envelope plasmid
pMD2.G, and packaging plasmid pSPAX2 (kindly provided
by J. Silvio Gutkind) were transiently transfected into human
embryonic kidney 293FT cells (Life Technologies) using ExGen
500 (Fermentas Inc., Glen Bernie, MD), and the supernatant
containing vesicular stomatitis virus (VSV)-G glycoprotein-
pseudotyped lentiviral vector particles was collected and
purified. Lentiviral vector particles were titered by FACS and
re-suspended at a concentration ∼2 million transducing viral
particles per 0.5 microliter.
Knockdown efficiency of shRNA was tested by Lipofectamine
2000 (Life Technologies Corp., Grand Island, NY)-mediated
transfection of mouse neuronal cell line N1E-115 cells with
the Dicer1 targeting or nonsense sequence cloned into pSuper
(Addgene, Cambridge, MA) for 24 h. Total RNA was isolated
from transfected cells using the RNAeasy purification kit
(Qiagen Inc., Valencia, CA), and Real-time quantitative reverse
transcription (qRT)-PCR was performed using the TaqMan
Universal PCRMasterMix (Applied Biosystems, Foster City, CA)
and Dicer1-specific primers 5′CTTGGATTCCTGGTGGAAGA-
3′ (forward) and 5′GAGCCCTGAGAATGGATGAA-3′ (reverse)
and cyclophilin-like 4 control gene primers 5′TGTTTCCTCATC
AGCACAGG-3′ (forward) and 5′AGGTCAGTGCCGAGTGTC
TT-3′ (reverse). Real-time qRT-PCR parameters were as follows:
denaturing at 95◦C for 15 min and annealing/extension at 60◦C
for 1 min for a total of 30 cycles performed in the 7300 Real-time
PCR System (Applied Biosystems, Foster City, CA). Normalized
expression was calculated using the comparative Ct method and
fold change was derived from the equation 2−11Ct.
Surgery, Lentiviral Particle Injection, and
Tolerance Assessment
Lentiviral vector particles containing shRNA targeting Dicer1
or nonsense sequence (control) was injected bilaterally into
the PFC of B6 mice. The stereotaxic coordinates were as
follows: anterior-posterior +1.70 mm, medial-lateral ± 0.6 mm,
dorsal-ventral −1.75 mm (relative to Bregma). Packaged viral
particles (∼2million transducing units) were injected at a volume
of 0.5 microliters per hemisphere at a rate of 0.25 µl/min (2
min/injection/hemisphere, 0.26 mm needle diameter, Plastics
One, Roanoke VA). The needle was left in for an additional 2 min
to allow the solution to diffuse. Mice were treated with rimadyl
(5.0 mg/kg, i.p.) once per day to provide analgesia for 2 days.
Four weeks following shRNA injection, the mice were treated
with an ED90 dose of morphine (31.2 mg/kg) or saline once
every other day over a 5-day period (total 3 treatments) and
assessed for tolerance by the hot plate test following the last
treatment as described in detail above. Four experimental groups
of B6 mice were used: Dicer1 shRNA-morphine (ED90); Dicer1
shRNA-saline; Nonsense shRNA-morphine (ED90); Nonsense
shRNA-saline. Brains were harvested for immunohistochemistry
confirmation.
Immunohistochemistry
Lentiviral-mediated shRNA placement and expression was
analyzed by immunohistochemistry with anti-GFP and anti-
Dicer1 antibodies. Each mouse was anesthetized with ketamine-
(100 mg/kg, i.p.) and xylazine- (16 mg/kg, i.p.), 10 min later
perfused with 4% paraformaldehyde, and brains were extracted.
The brains were immersed in formalin for 24 h and then switched
to 18% sucrose solution for 48 h. The brains were snap frozen
in dry ice and stored in a −80◦C freezer until further use. The
formalin fixed brains mounted in OTC embedding compound
(Thermo Fisher Scientific, Waltham, MA) were sectioned on a
−20◦C cryostat (Leica Microsystems Inc., Wetzlar, Germany) at
20 µm intervals and mounted serially on poly-L-lysine-coated
slides and stored in −80◦C until labeling. The slices were rinsed
with 1X PBS three times for 5 min, rinsed two times for 5
min in 0.1% glycine (dissolved in 1X PBS), followed by a 1 h
incubation in 50 mM ammonium chloride (NH4Cl dissolved in
1X PBS). Slices were rinsed again three times for 5 min with 1X
PBS, blocked in the blocking buffer for 1 h (3% serum, 0.3%
triton X, dissolved in 1X PBS), and then incubated with the
primary antibodies overnight at 4◦C (1% serum, 0.3% triton
X, dissolved in 1X PBS). The primary antibodies were anti-
GFP (chicken anti-GFP, #A10262; 1:1000 dilution; Invitrogen,
Carlsbad, CA; A11122) and anti-Dicer1 (rabbit anti-Dicer1,
#71691; 1:250 dilution; Novus Littleton, CO). Slices were then
rinsed three times for 5 min with 1X PBS and were treated
with the appropriate secondary antibodies for 2 h (1% serum,
0.3% triton X, dissolved in 1X PBS): at 1:200 dilution with
goat anti-rabbit red Alexafluor-594 and goat anti-chicken green
Alexafluor-488 (Molecular Probes, Eugene Oregon). Slices were
rinsed one time for 5 min with 1X PBS and then stained with
DAPI for 30 min (300 nM: 1 µl DAP1 into 1 ml H2O; above
solution in 49 ml of 1X PBS). DAPI counterstain was utilized
to determine the cytoarchitecture of anatomical regions. DAPI
was washed off by rinsing three times for 5 min in 1X PBS
and one time in double distilled H2O. Slides were coverslipped
and images were captured on an Olympus (Center Valley, PA)
fluorescence microscope and an Olympus FluoView 500 confocal
microscope (Center Valley, PA). The positive fluorescence cells
were mapped within the PFC at the location of the injection
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site using the mouse brain stereotaxic coordinates (Paxinos and
Franklin, 2001). The GFP-positive cells were mapped within
the PFC at the location of the injection site using the mouse
brain stereotaxic coordinates (Paxinos and Franklin, 2001), and
fluorescence pixel values for Dicer1 within GFP-positive cells
were quantified at 20X magnification using Photoshop 12.0
software.
miRNA Expression Profiling
Brain tissue was harvested in a subset of the B6 mice 3 h after the
end of tolerance testing on the last test day (see analgesia testing
above; n = 4 each for saline and morphine treated mice). Each
mouse was euthanized by CO2 asphyxiation. A Plexiglas brain
mold (David Kopf Instruments, Tujunga, CA) was used to slice
the fresh whole brain into an appropriate coronal slice. Using the
atlas of Paxinos and Franklin (2001) as a reference, the PFC was
taken in the following parameters: interaurally 5.90–4.90 mm,
from the dorsal-most point to 2.25 mm ventrally at a medial-
lateral width of 1 mm centered on midline. The PFC dissection
includes the prelimbic, infralimbic, cingulate and portions of the
secondary motor cortex. MiRNA isolation from PFC, miRNA
quality control, labeling and hybridization onto Agilent SurePrint
Mouse miRNA microarrays, and data extraction, normalization
and statistical analyses were performed as previously described
(Wang et al., 2010). Statistical differences in miRNA expression
between saline and morphine administration were analyzed by
an ANOVA with 10% false discovery rate (FDR) for multiple
test correction on the ArrayStat software package (Amersham
Biosciences Corp.). MiRNA data has been deposited to the Gene
Expression Omnibus (GEO) and can be assessed using Accession
number GSE75893.
Real-Time qRT-PCR Validation
Validation of miRNA expression array results was accomplished
by qRT-PCR of total RNA isolated from separate B6 and
D2 animals (see analgesia testing above; n = 6, 6, 4, and
4 for B6 saline, B6 morphine, D2 saline, and D2 morphine,
respectively). Tolerance was assessed as described above. Testing
and PFC harvest was conducted as described above. Isolation
of total RNA from PFC and qRT-PCR was performed using
the NCode EXPRESS SYBR GreenER microRNA qRT-PCR Kit
(Invitrogen, Carlsbad, CA), as previously described (Wang et al.,
2010). Briefly, poly(A)-tailed reverse transcription (RT) reaction
products were mixed with Express SYBR green qPCR SuperMix,
miRNA-specific forward primer (Supplementary Table 1) and
universal qPCR primer and subjected to 40 cycles of 95◦C for
15 s, and 60◦C for 1 min performed in a 7300 Real-time PCR
System (Applied Biosystems, Foster City, CA). U6 snRNA was
used as the internal standard reference in the qRT-PCR reactions.
Normalized expression was calculated using the comparative Ct
method and fold change was derived from the equation 2−11Ct
for each miRNA.
Integrative Analysis of miRNA and mRNA
Microarray Data
Target mRNA predictions were determined for the differentially
expressed miRNAs, and the number of target mRNAs were
cross-referenced with 78 differentially regulated mRNAs
determined in the earlier expression profiling analyses
(Tapocik et al., 2009). The mRNA data from Tapocik et al.
(2009) can be assessed at the Journal of Neuroscience website at
http://www.jneurosci.org/. MiRNA target analysis was conducted
using the microRNA.org website (Betel et al., 2008). “Good”
miRSVR and PhastCon scores with cutoffs based on algorithms
in microRNA.org were used to determine predicted miRNA-
mRNA interactions (Betel et al., 2010). The scores determined
proper association of miRNA expression patterns with our
experimentally observed mRNA expression results. Follow-up
targets for confirmation were prioritized based on information
provided by miRNA-mRNA expression pairing, hypergeometric
testing (see below), DAVID Gene Ontology, gene network and
canonical analysis (Ingenuity Pathway Analysis, Redwood City,
CA).
Hypergeometric Testing
To determine whether any of the differentially expressedmiRNAs
“over-targeted” genes that were differentially regulated, we
conducted an over-representation analysis of targeting events,
similar to that used by Lewohl et al. (2011). Hypergeometric
tests were conducted for each differentially expressed miRNA.
Correction for multiple testing was carried out using the linear
step-up method for a 10% FDR (Benjamini and Hochberg,
1995).
miR-3′UTR Binding Luciferase Assay
N2A cells were grown on poly-D-lysine in 96-well format
to a 70–85% confluency and transfected using Lipofectamine
2000 (Life Technologies Corp., Grand Island, NY) with 200 ng
of psiCHECK2-Serpini1-3′ UTR plasmid and 5 pmol of Mus
musculus (mmu)-miR-27a, mmu-miR-9, or nonsense mimics
(Exiqon, Woburn, MA). At 48 h post-transfection, cells were
lysed and luciferase reporter activity was assayed using the
Dual-Luciferase Reporter Assay System (Promega, Madison,
WI). The activities of firefly and Renilla luciferases were
measured sequentially from a single sample in a FLUORstar-
BMG luminometer (IMGEN, Alexandria, VA) for 60 s each
immediately after addition of Luciferase Assay Reagent II for
firefly luciferase or Stop and Glo Reagent for Renilla luciferase.
Renilla luciferase values were normalized to control firefly
luciferase levels (transcribed from the same vector but not
affected by 3′ UTR tested) and averaged across 3–5 well
repetition, resulting in 3–5 technical and 3 biological replicates
for each condition (miR-9, 27-, 206, and nonsense control).
MiR-27a Regulation of Serpini1 Protein
Levels in Mouse Neuronal Cell Lines
Computational prediction that miR-27a targets Serpini1 was
verified by individually transfecting mouse neuronal cell lines
N2A and N1E115 with 5 pmol of mmu-miR-27a or nonsense
control mimic (Exiqon,Woburn, MA). At 48 h post-transfection,
lysates were isolated from cell lines for western blot analysis of
serpini1 (see below). Four and eight independent experiments
were performed in N1E-115 and N2A cells, respectively. Each
independent experiment was defined as a culture of cells treated
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with NS control mimic and a separate culture treated with the
miR-27a mimic.
Western Blot Analysis
Cell lysates from PFC of B6 mice or neuroblastoma cell lines
(N2A and N1E115) were subjected to western blot analysis
as previously described (Wang et al., 2010). Briefly, protein
concentration of lysates was determined using NanoOrange
Protein Quantitation Kit (Molecular Probes, Invitrogen, Eugene,
OR). Twenty-five micrograms of protein lysate from cell lines
or 50 µg from PFC was separated using standard SDS-PAGE
with precast 4–20% gels (BioRad, Hercules, CA) and transferred
to PVDF membranes using standard transfer conditions. We
employ two approaches in order to ensure equal loading of
total protein lysate in each lane of the western blot. First,
we stain the blots with ponceau to ensure overall equal
loading of protein lysates. Second, we normalize our calculations
with beta-actin. Next, membranes were washed and blocked
for at least 1 h using BSA or powdered milk, followed by
sequential incubations of primary antibody against Serpini1
and secondary antibody conjugated to horseradish peroxidase
(HRP). Afterwards, membranes were washed and incubated
with enhanced chemiluminescence substrate (Perkin Elmer,
Waltham, MA) for autoradiography. Films were scanned using
a Personal Densitometer SI (Molecular Dynamics, Sunnyvale,
CA) and protein bands quantified using ImageQuant software.
Membranes were stripped and then incubated with β-actin
antibody for quantification and normalization. All antibodies
used in this study are mouse monoclonal anti-Serpini1 and anti-
β-actin (Sigma-Aldrich, Saint Louis, MO), rabbit polyclonal anti-
Dicer1 (Novus Biologics, Littleton, CO), and goat anti-mouse and
anti-rabbit secondary antibody conjugated to HRP (Santa Cruz
Biotechnology, Santa Cruz, CA).
RESULTS
Causal Role of Dicer1 in Response to
Chronic Morphine
We previously established that Dicer1 mRNA expression was
negatively correlated with the %MPE of morphine after COA
(Tapocik et al., 2009). Therefore, we conducted in vivo studies
to identify the causal role of Dicer1 in response to chronic
morphine. Prior to initiating the in vivo studies, the effectiveness
of an EmGFP-Dicer1 shRNA cassette to knockdown Dicer1
mRNAwas tested by transducingmouseN1E-115 neuroblastoma
cells. Transfection resulted in an 82 ± 4.5% knockdown
compared to nonsense control as determined by qRT-PCR (t
= 4.0, df-6 P = 0.007). In vivo, disrupting Dicer1 expression
via shRNA in the PFC of B6 mice did not alter baseline
sensitivity to thermal stimuli; vehicle baseline latencies were
6.4, 7.6, and 7.7 s for nonsense vehicle controls and 6.4,
9.4, and 7.4 s for Dicer1 shRNA controls across injection
days 1, 2, and 3, respectively. However, Dicer1 shRNA treated
mice failed to develop tolerance compared to the nonsense
treated control mice [F(Virus) df (1, 9) = 7.31; p = 0.0269]
(Figure 1A). In each of the Dicer1 shRNA injected brains, there
was diminished expression of perinuclear Dicer1 protein in the
FIGURE 1 | shRNA targeting Dicer1 in B6 mice significantly reduced
the development of tolerance. (A) The %MPE following 31.2 mg/kg
morphine (s.c.) across three injections each spaced 48 h apart significantly
decreased in nonsense control mice and not in Dicer1 shRNA treated mice.
*Significantly different than nonsense control (P < 0.030, 0.001); (n = 6,5 for
Dicer1 shRNA and nonsense controls, respectively). (B),
Immunohistochemistry was performed on behaviorally phenotyped animals in
(A). GFP-positive PFC cells indicate successful transduction with lentivirus
carrying Dicer shRNA. GFP-staining was observed along the injection track in
the PFC (a). Bracketed region in A shown enlarged (a′). To examine the
efficacy of the shRNA-mediated Dicer1 knockdown in GFP-positive PFC cells,
Dicer protein was co-stained by immunofluorescence with a Dicer1-specific
antibody (red). Nuclear DNA was co-stained with DAPI (blue channel). In
GFP-positive PFC cells containing Dicer1 shRNA (solid arrows in b,c),
perinuclear Dicer1 expression is significantly reduced (solid arrows in b′,c′ ). By
comparison, untransduced neighboring cells not expressing GFP (open arrows
in b,c) have high expression of Dicer1 (open arrows in b′,c′ ). In cells
transduced with lentivirus delivering nonsense shRNA control, GFP-positive
cells (closed arrows in d) retained strong perinuclear Dicer1 protein expression
(closed arrows in d′ ). Immunofluorescent images are representative from six
(Continued)
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FIGURE 1 | Continued
animals transduced with lentivirus carrying Dicer1 shRNA and chronically
treated with morphine, and five animals transduced with lentivirus carrying
nonsense shRNA control and chronically treated with morphine. Scale bars
(inset white lines) in (a) = 100 µm and (b–d) = 25 µm. (C) Quantification of
Dicer1 immunofluorescence in the PFC (B). Bar graph represents relative
Dicer1 protein levels in GFP-expressing cells from control (nonsense shRNA)
and Dicer1 shRNA-treated animals. A total of 31 and 40 well-demarcated
GFP-expressing cells from control and Dicer1 knockdown animals,
respectively were quantified as described in Materials and Methods Section.
*Significantly different from nonsense shRNA-treated animals (P < 0.0001).
FIGURE 2 | Tolerance to the analgesic effects of morphine in B6 and D2
mice. The %MPE following morphine (s.c.) across three injections each
spaced 48 h apart significantly decreased in B6 but not D2 treated mice. *P <
0.05, **P < 0.01, significantly different than B6 mice (n = 10, 8 for B6, and D2
mice, respectively).
GFP-positive cells (Figure 1B). In contrast, animals injected in
the PFC with nonsense shRNA exhibited strong expression of
perinuclear Dicer1 protein in the GFP-positive cells (Figure 1B).
Quantified fluorescence pixel values for Dicer1 within GFP-
positive cells revealed a significant reduction following Dicer1
shRNA-treatment (t = 5.20, p< 0.0001) (Figure 1C).
Changes in miRNA Expression Are
Associated with Tolerance Susceptibility
Analgesic testing following repeated morphine administration
was conducted in B6 and D2 mice to provide brain tissue
for miRNA expression profiling and qRT-PCR confirmation of
candidate miRNA targets. As previously demonstrated (Tapocik
et al., 2009), the analgesic effect of morphine significantly
decreased following repeated morphine administration in B6
mice and not in D2 mice [Figure 2; F(Strain) df (1, 15) = 22.02;
p = 0.0003; F(Injection as repeated measure in B6 mice) df (2, 8) = 14.91;
p= 0.002; D2 with injection as repeated measure ns]. To test the
hypothesis that miRNAs participate in the behavioral response
to COA, miRNA profiling was conducted in a subset of the B6
vehicle and morphine-treated mice (n = 4 each). Confirmation
of candidate miRNA was conducted in separate B6 mice and
contrasted to the level of expression in a genotype that does
not develop analgesic tolerance (D2). The miRNAs profiled
on Agilent SurePrint arrays, which identified 47 significant
differentially expressed miRNAs in the PFC of morphine- vs.
saline-treated mice (ANOVA with 10% FDR; 33 up, 14 down)
(Table 1). We selected 6 differentially expressed miRNAs for
qRT-PCR validation in separate saline and morphine-treated
B6 mice (Figure 3). Four out of the six miRNAs undergoing
validation exhibited congruence between miRNA profiling and
qRT-PCR results, ranging from ∼2-fold down-regulation to ∼2-
fold up-regulation [Table 1 and Figure 3; miR27a: t(10) = 2.848,
p = 0.0173; miR146b: t(10) = 3.448, p = 0.0063; miR505:
t(10) = 10.471, p = 0.0001; miR202-5p: t(10) = 3.222, p =
0.0091]. Alterations in miR-126-5p and miR-335-3p were not
confirmed. Given that the miRNA profiling and qRT-PCR
results were obtained from separate animals, the four out of
six validation success rate (67%) can be viewed as reasonable.
Furthermore, we took advantage of the qualitative contrast in
the development of tolerance between B6 and D2 mice (D2
mice do not develop tolerance under the present conditions, see
Figure 2) by quantifying expression of these same miRNAs in
D2 animals. COA does not alter miRNA in these non-tolerant
D2 providing increased support to these particular miRNA as
high value candidates (miR27a; miR146b; miR505; miR202-5p,
all ns). Supplementary Figure 1 shows qRT-PCR quantification
of miRNAs in PFC of B6 and D2 animals treated with saline. At
baseline (saline treated) expression level of miR27a and miR146b
were significantly greater in D2 mice compared to the B6 mice
while miR505 was equivalent and miR202-5p was significantly
less than the B6mice [miR27a: t(8) = 8.411, p= 0.0001; miR146b:
t(8) = 3.448, p = 0.0007; miR505: t(8) = 0.261, ns; miR202-5p:
t(8) = 3.000, p= 0.0171].
Integrative Analysis of miRNA and mRNA
Microarray Data
To detect coordinated patterns of miRNA and mRNA expression
changes induced by chronic morphine administration, we
performed miRNA-mRNA expression pairing analysis with our
previous mRNA data set (Tapocik et al., 2009). We identified
cases where the expression of a miRNA species and its
putative target mRNAs (target prediction based on “Good score”
values from microrna.org) were altered in the opposite or
same direction following COA. We have previously used this
computational approach to identify predicted miRNA-mRNA
pairings that had a high probability of successful validation
(Wang et al., 2015). We found 30 miRNAs targeting 59 out of
77 mRNAs of our original mRNA data set that fulfilled this
condition. The results of the expression pairing analysis are
given in Tables 2A,B. Hypergeometric testing determined that
seven differentially expressed miRNAs were predicted to “over-
target” mRNAs (Supplementary Table 2) as determined by a
hypergeometric significant p-value (p < 0.05), however none of
these passed the threshold for FDR.
We chose to investigate and validate the predicted miR-27a-
Serpini1 mRNA pairing due to a number of compelling reasons.
First, as regards miR-27a, there were an unusually high number
of PFC mRNAs predicted to be targeted by miR-27a (18 targets
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TABLE 1 | miRNA altered by chronic morphine in B6 mice (highlighted
miRNA further confirmed by qRT-PCR).
Up-regulated Fold Down-regulated Fold
mghv miR-M1-9 4.38 miR-382* –1.81
miR-202-5p 4.07 miR-154* −1.49
miR-194 3.46 miR-29b −0.69
miR-29b* 2.44 miR-19b −0.68
miR-672 2.21 miR-338-3p −0.59
miR-197 2.13 miR-199b −0.57
miR-467a-1* 1.94 miR-1 −0.52
miR-30b* 1.83 miR-34c −0.48
miR-126-5p 1.76 miR-146a −0.47
miR-152 1.62 miR-218 −0.40
miR-469 1.55 miR-27a −0.37
miR-184 1.46 miR-9 −0.37
miR-378* 1.37 miR-872 −0.35
miR-669a 1.30 miR-146b −0.34
miR-92b 1.26
let-7d* 1.26
miR-505 1.12
miR-101b 1.05
miR-429 0.95
miR-490 0.74
miR-320 0.73
miR-22* 0.72
miR-574-3p 0.68
miR-342-5p 0.67
miR-376a 0.60
miR-483* 0.58
miR-700 0.55
miR-298 0.54
miR-690 0.53
miR-380-3p 0.46
miR-376b 0.43
miR-423-5p 0.41
miR-335-3p 0.38
total). Second, as regards Serpini1 mRNA, the highest mirSVR
score for any target was for Serpini1. This particular miRNA was
also found to be significantly correlated with analgesic tolerance
as determined from data collected in (Tapocik et al., 2009)
(Figure 4A). Third, the predicted target, Serpini1 is contained
within a relevant analgesia QTL (Belknap and Crabbe, 1992), and
lastly, Serpini1 is intricately involved in modulating an important
neuroplastic element in response to chronic drug administration,
namely altered dendritic spine density (see Discussion).
miR-27a Modulates Serpini1 mRNA
Expression and Protein Levels
The mouse Serpini1 3′-untranslated region (3′-UTR) is
comprised of 1599 nucleotides. Bioinformatics analysis using
microRNA.org identified 2 conserved mmu-miR-27a target sites
in the Serpini1 3′-UTR, at positions 225 and 435 (Figure 4B).
Unexpectedly in a dual luciferase assay employing an mRNA
reporter construct of the luciferase open reading frame fused
to the Serpini1 3′UTR, luciferase protein expression was
significantly increased by miR-27a [t(4) = 8.46, p = 0.011]
(Figure 5) and another putative targeting miRNA, miR-9 [t(4) =
17.56, p < 0.001]; but not miR-206 (p > 0.05), a miRNA with no
binding sites to Serpini1, and a nonsense sequence control.
To determine if miR-27a has the ability to increase Serpini1
protein levels, we transfected two cell lines, mouse N2A andN1E-
115 neuroblastoma cells, with a miR-27a mimic and measured
protein levels of Serpini1. MiR-27a significantly increased the
level of Serpini1 protein by>3-fold compared to cells transfected
with nonsense mimic control [N1E-115: t(6) = 3.26, p = 0.017,
N2A: t(14) = 2.40, p= 0.031, Figure 6].
In order to determine if there was a link between the proposed
chain of events (COA→decreased miR-27a→decreased Serpini1
mRNA→decreased Serpini1 protein), Serpini1 protein levels
were characterized in analgesic tolerant B6 mice [analgesic
tolerance: n= 6 saline, 7 morphine; F(Injection #) df (2, 6) = 4.965; p
= 0.0047; data not shown, results not different from those shown
in Figure 2]. From these phenotyped animals, we harvested high
quality PFC from n = 4 saline-treated and n = 4 morphine-
treated animals for western analysis of Serpini1 protein levels.
COA resulted in a significant decrease in PFC Serpini1 protein
compared to saline-treated animals [t(6) = 3.36, p = 0.015,
Figure 7].
Our findings can be summarized as follows: (a) COA
decreases the expression of miR-27a in mice that develop
tolerance (Figures 2, 3), (b) miR-27a increases, not decreases,
serpini1 expression (Figures 5, 6), thus decreased miR-27a may
decrease Serpini1 expression, (c) COA decreases Serpini1 protein
levels in the PFC (Figure 7), and (d) Serpini1 is negatively
correlated with tolerance (less Serpini1 is associated with greater
tolerance; Figure 4A). Thus, a decrease in miR-27a may lead
to a decrease in Serpini1 that in turn leads to tolerance. In
order to determine if there was a causal association between
miR-27a alteration of Serpini1 expression and the development
of analgesic tolerance, we characterized the development of
tolerance in Serpini1 KO animals and the corresponding B6
control group (Figure 8). Baseline nociception did not differ
between the genotypes. Acute morphine administration (42.0
mg/kg) resulted in equivalent degree of analgesia following
the first injection, thus Serpini1 knockout did not alter acute
sensitivity. In contrast, chronic morphine administration (42.0
mg/kg per injection) led to a rapid and full degree of tolerance by
the second injection in the B6 mice, however Serpini1 KO mice
took three injections to reach the same degree of full tolerance
[ANOVA F(Genotype × Injection #) df (2, 10) = 4.078; p= 0.050; post-
hoc Injection # 2 KO vs. B6 p = 0.0387]. These results suggest
that the process of reducing Serpini1 is a necessary factor in the
development of tolerance.
DISCUSSION
The overall goal of the study was to determine if miRNAs
are involved in mediating the neurobiological mechanisms
responsible for the development of analgesic tolerance following
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FIGURE 3 | qRT-PCR validation of miRNAs in prefrontal cortex of B6 and D2 animals treated with chronic saline or chronic morphine. Data are
presented as the mean ± SEM of 4–6 independent animals. *Significantly different from saline treated animals using a Student t test, P < 0.05. This cohort of animals
analyzed by qRT-PCR is an independent, replicate sample from the animals interrogated by miRNA microarray analysis.
COA. Two key findings support their involvement; first,
decreasing the expression of the rate-limiting enzyme in miRNA
production, Dicer1, prevents the development of tolerance
and second, the expression of a select number of miRNAs
is altered following the administration of pharmacologically-
relevant doses of morphine. Further confirmation was obtained
by demonstrating differential expression of key miRNAs in
tolerance susceptible (B6) vs. unsusceptible genotypes (D2).
Interestingly, despite COA producing an increase in Dicer1 in
tolerant mice, 14 of the 47 miRNAs significantly altered by
COA were down-regulated. The discord between Dicer1 levels
and down-regulated miRNAs could reflect Dicer-independent
processing (Bhinder et al., 2014; Liu et al., 2015) that may
even give rise to inverse production levels (possibly due to
competitive Dicer loading; Liu et al., 2015). This point is relevant
since we chose to further investigate a miRNA that was down-
regulated, namely miR-27a. Several factors led us to investigate
miR-27a, such as the very high number of putative mRNA targets
within previously identified COA-relevant mRNAs in the same
brain region and its putative targets involved in neuroplasticity.
Furthermore, we chose to investigate its predicted mRNA
target, Serpini1, due to its high mirSVR score and role in
neuroplasticity (Parmar et al., 2002; Navarro-Yubero et al.,
2004; Borges et al., 2010; Lee et al., 2012). The experiments
confirmed miR-27a regulation of Serpini1 mRNA and protein as
well as demonstrating altered analgesic tolerance development in
Serpini1 KO animals. Overall, the study supports a significant
and targetable role for miRNA in the development of analgesic
tolerance.
The neurobiological consequences of COA likely involve
coordinated and complex neuroadaptations. Altered gene
expression is a plausible means for inducing these long-term
changes. Studies conducted by our laboratory (Tapocik et al.,
2009, 2013) revealed a network of gene expression changes
occurring in canonical pathways involved in neuroplasticity, and
uncovered miRNA processing as a prime candidate coordinating
these changes in response to COA. In particular, mRNA
coding the protein responsible for processing miRNAs, Dicer1,
was positively correlated with the development of analgesic
tolerance in the PFC. These results along with several studies
demonstrating miRNA involvement in cellular response to acute
opioid administration (Wu et al., 2008, 2009, 2013; Sanchez-
Simon et al., 2010; Hwang et al., 2012; Zheng et al., 2012; Ni et al.,
2013; Gonzalez-Nunez et al., 2014; Lu et al., 2014; Xu et al., 2015)
and miRNA involvement in neuroplasticity that may be relevant
to decreased spine density seen in the PFC (Robinson et al., 2002;
Robinson and Kolb, 2004), gave rise to the hypothesis that key
miRNAs modulate the development of analgesic tolerance. As a
first test of this hypothesis, regionally targetedDicer1 knockdown
(via shRNA) had the anticipated consequence of eliminating the
development of tolerance in B6 mice. These in vivo findings
strongly supported the involvement of miRNA processing in the
acquisition of tolerance. MiRNA expression profiling following
therapeutically relevant doses identified a small, core set of
COA-regulated miRNAs (∼6% of the characterized miRNAs).
Bioinformatic tools were utilized to identify miRNAs with a high
number of valued mRNA targets in our previous microarray
study for qRT-PCR validation (miR’s 27a, 9, 483, 505, 146b, 202).
Further corroboration of their importance in analgesic tolerance
was confirmed by the lack of expression change in a genotype that
does not develop tolerance following pharmacologically-relevant
doses (D2; Tapocik et al., 2009).
Several miRNAs have previously been demonstrated to
moderate the consequences of COA (Hwang et al., 2012).
For example, COA-induced increases in a miRNA postulated
to alter OPRM1 mRNA expression, Let-7, correlates with
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TABLE 2A | Negatively correlated miRNA-mRNA pairings in PCR validated
miRNAs.
miR name miR
change
miR Log2
value
mRNA miRSVR
score
mRNA
change
mmu-miR-146b ↓ −0.3362 Enpp5 −1.0510 ↑
↓ Pet112l −1.0474 ↑
↓ Afmid −1.0327 ↑
↓ Ccna2 −0.6094 ↑
↓ Baiap2l1 −0.3049 ↑
↓ Phf17 −0.2832 ↑
↓ Pcbp2 −0.1396 ↑
↓ Dicer1 −0.1357 ↑
↓ C86695 −0.1061 ↑
mmu-miR-202-5p ↑ 4.0723 Dlgap1 −1.2131 ↓
↑ AI593442 −1.0566 ↓
↑ Rps6ka5 −0.9715 ↓
↑ Meis1 −0.7075 ↓
↑ Fstl1 −0.6275 ↓
↑ Atp2b2 −0.4273 ↓
↑ Rab6b −0.2834 ↓
↑ Ubqln1 −0.1476 ↓
↑ Ppp1r9a −0.1379 ↓
↑ Ralgps1 −0.1185 ↓
mmu-miR-27a ↓ −0.3690 Fmn2 −0.7565 ↑
↓ Dicer1 −0.7044 ↑
↓ Rufy3 −0.6805 ↑
↓ Dusp9 −0.3455 ↑
↓ Baiap2l1 −0.2262 ↑
mmu-miR-505 ↑ 1.1166 Meis1 −1.2283 ↓
↑ Serpini1 −0.8085 ↓
↑ Ralgps1 −0.4115 ↓
↑ Canx −0.3364 ↓
↑ Hic2 −0.2643 ↓
↑ Kcnj4 −0.1538 ↓
↑ Vps26a −0.1231 ↓
Green up arrow: up-regulated in morphine vs. saline. Red down arrow: down-regulated
in morphine vs. saline.
analgesic tolerance and targeted deletion of Let-7 attenuates
the development of analgesic tolerance (He et al., 2010; He
and Wang, 2012). In the current study Let-7b was increased
and two additional putative OPRM1 mRNA targeting miRNAs
were decreased [miR-154 and miR-199b, (He and Wang,
2012)] but not miR-134, (Ni et al., 2013). Additional studies
demonstrate altered miRNA expression in CNS tissue following
opioid administration; miR-190 (Zheng et al., 2010a), miR-133b
(Sanchez-Simon et al., 2010), miR-28, -125b, -150 and -382
(Wang et al., 2011), miR-23b and -339 (Wu et al., 2008, 2009,
2013), miR-339 (Zheng et al., 2012), miR-103 and -107 (Lu et al.,
2014), miR-21 and -146a (Strickland et al., 2014), and miR-124
(Qiu et al., 2015). However, none of the aforementioned miRNAs
were found to be differentially-regulated in the current study.
Treatment conditions and tissue source are likely explanations
TABLE 2B | Positively correlated miRNA-mRNA pairings in PCR validated
miRNAs.
miR name miR
change
miR Log2
value
Gene miRSVR
score
mRNA
change
mmu-miR-146b ↓ −0.3362 Gripap1 −0.6473 ↓
↓ Fstl1 −0.4896 ↓
↓ Dlgap1 −0.4727 ↓
↓ Vps26a −0.2555 ↓
↓ Gosr2 −0.1763 ↓
↓ Gprasp1 −0.1232 ↓
↓ Zfand6 −0.1105 ↓
↓ Serpini1 −0.1097 ↓
mmu-miR-27a ↓ −0.3670 Serpini1 −1.9421 ↓
↓ Ppp1r9a −0.8020 ↓
↓ Ubqln1 −0.7975 ↓
↓ Rps6ka5 −0.7940 ↓
↓ Gosr2 −0.7700 ↓
↓ Canx −0.7310 ↓
↓ AI593442−0.5274 ↓
↓ Nsf −0.4902 ↓
↓ Dgkb −0.4384 ↓
↓ Dlgap1 −0.3411 ↓
↓ Atp2b2 −0.2743 ↓
↓ Zfand6 −0.1456 ↓
↓ Nufip1 −0.1278 ↓
mmu-miR-505 ↑ 1.1166 Sap25 −1.2974 ↑
↑ Parp11 −1.0018 ↑
↑ Srbd1 −0.6136 ↑
↑ Dicer1 −0.3529 ↑
↑ Txnip −0.2797 ↑
↑ Phf17 −0.1855 ↑
↑ Ccnf −0.1480 ↑
Green up arrow: up-regulated in morphine vs. saline. Red down arrow: down-regulated
in morphine vs. saline.
for the discrepancies, for example miR-103 and -107 were only
differentially expressed in striatum and not PFC (Lu et al., 2014).
MiRNAs frommacrophages were altered bymorphine (miR-146a
and -423-5p; Dave and Khalili, 2010) and in our study as well
(although in opposite directions). The current set of experiments
are the first to report the confirmed association of miRNAs miR-
27a, -9, -483, -505, -146b, and -202) using pharmacologically-
relevant doses of morphine.
Once a core set of miRNAs were identified and confirmed
we performed miRNA-mRNA expression pairing analysis with
our previously collected mRNA data to identify cases where the
expression of a miRNA species and its putative target mRNAs
(derived from microrna.org) were altered in the opposite or
same direction following COA (Wang et al., 2015). We chose to
investigate and validate the predicted miR-27a-Serpini1 mRNA
pairing due to (a) the unusually high number of PFC tolerance-
related mRNAs predicted to be targeted by miR-27a (18 out of
78), (b) the high miRSVR score for miR-27a targeting Serpini1,
(c) the fact that the Serpini1 is contained within a relevant
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FIGURE 4 | (A) Correlation between Dicer1 mRNA expression and tolerance
(as measured by a decrease in the maximal possible effect; %MPE) following 3
morphine administrations in 4 genotypes (data derived from (Tapocik et al.,
2009)). (B) Map of the putative binding sites of miR-27a on the 3′UTR of
Serpini1 and mirSVR scores (derived from microRNA.org). The combined
mirSVR score = −1.9421. Mmu, Mus musculus; Rno, Rattus norvegicus;
Cpo, Cavia porcellus; Ocu, Oryctolagus cuniculus; Hsa, Homo sapiens.
analgesia QTL (Belknap and Crabbe, 1992; Belknap et al., 1995;
Bergeson et al., 2001), (d) the demonstrated positive correlation
between Serpini1 mRNA levels and the prevention of analgesic
tolerance (see Figure 4A), and (e) the fact that Serpini1 is
intricately involved in modulating an important neuroplastic
element in response to chronic morphine administration, namely
altered dendritic spine density (Robinson et al., 2002; Robinson
and Kolb, 2004; Ballesteros-Yanez et al., 2007; Zheng et al.,
2010b; Kobrin et al., 2015). In vitro reporter assay confirmed
the targeting of the Serpini1 3′-untranslated region by miR27a.
Interestingly, miR27a was found to positively regulate Serpini1
mRNA and protein levels in multiple neuronal cell lines and to be
associated with the development of morphine-induced analgesic
tolerance.
The up-regulation of Serpini1 mRNA and protein by
miR27a may appear at first sight surprising, given that
miRNAs have typically been associated with down-regulation
of gene expression (i.e., translation repression and/or mRNA
degradation) (He and Hannon, 2004). More recently, notable
examples of translational activation by miRNAs have appeared in
the literature (Vasudevan et al., 2007; Orom et al., 2008; Jacobsen
et al., 2010). These miRNAs have been shown to bind cis-acting
sites that are adjacent/overlapping AU-rich motifs in the 3′-
UTR of the targeted mRNA, as is the case for miR27a/Serpini1
3′-UTR (see Figure 4B). AU-rich motifs near miRNA binding
sites enhance translational efficiency of the targeted mRNA by
mechanisms that remain to be fully elucidated (Vasudevan et al.,
2007; Jacobsen et al., 2010).
FIGURE 5 | Putative targeting miRNA’s miR-27a and miR-9 increase
Serpini1 expression. Bar plots represent luciferase activity measured in N2A
cells cotransfected with either miR-27a, miR-9, miR-206 mimic, or nonsense
mimic, and a luciferase reporter plasmid carrying the 3′-UTR of Serpini1.
Renilla luciferase activity was normalized by firefly luciferase expression levels
and is presented as percentage of activity achieved by the 3′-UTR of Serpini1
in the presence of mimics (miR27a, miR-9, miR-206, nonsense). MiR-27a and
miR-9 target Serpini1 (mirSVR scores −1.9, −0.7, respectively) while miR-206
does not. MiR-27a and miR-9 increased Serpini1 expression, ***p < 0.05.
The results thus far support the hypothesis that in mice
readily developing tolerance under pharmacologically-relevant
conditions, COA decreases the expression of miR-27a, which in
turn decreases serpini1 mRNA and protein expression thereby
leading to analgesic tolerance. In order to determine if there
was a causal association between miR-27a alteration of Serpini1
expression and the development of analgesic tolerance, we
characterized the development of tolerance in Serpini1 KO
animals. Several possible outcomes were hypothesized to occur;
(a) lack of analgesic effect in KO mice upon first injection
that would reflect an already “tolerant” state, (b) a faster rate
of tolerance if Serpini1 needs to be at a certain level to show
tolerance or (c) a slower rate of tolerance since the dynamic
process of reducing or withdrawing Serpini1 is a necessary
factor in the development of tolerance or (d) no effect due to
developmental compensation. Acute morphine administration
resulted in equivalent degree of analgesia, thus Serpini1 knockout
did not alter acute sensitivity (eliminate “a” as possibility).
In contrast, chronic morphine administration led to a rapid
and full degree of tolerance by the second injection in the
B6 mice, whereas Serpini1 KO mice took three injections
to reach the same degree of full tolerance (eliminating “b,”
supporting “c”). These results provide evidence to support a
role for miR27a and Serpini1 in the behavioral response to
COA.
MiRNAs are prime candidates to mediate network-like
changes in response to chronic drug administration. These
molecules are thought to regulate as much as one-third of
the transcribed genome, can mediate short and long term
neuroplasticity and play a role in sculpting the dendritic
architecture (Kosik, 2006; Impey et al., 2010; Im and Kenny,
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FIGURE 6 | MiR27a up-regulates Serpini1 protein levels. Transfection of miR-27a mimic in mouse N1E-115 and N2A neuroblastoma cell lines resulted in
up-regulation of Serpini1 protein. Top panels, representative western blots from 4 to 8 independent experiments. Bottom panels, quantification of relative Serpini1
protein levels was calculated from Serpini1-to-actin densitometric ratios. Data are presented as the mean ± SEM from 4 to 8 independent experiments in N1E-115
and N2A cells, respectively. Each independent experiment is defined as a culture of cells treated with nonsense (NS) miRNA and a separate culture treated with the
miR-27a mimic. *Significantly different from nonsense (NS) mimic-treated cell lines using a Student t test, P < 0.05.
2012; Weiss et al., 2015; Xu et al., 2015). Differential miRNA
expression/processing and mRNA targeting may underlie the
neuroadaptations that mediate altered dendritic morphology in
the PFC and tolerance to the analgesic effects of morphine.
MiR-27a induced alterations in Serpini1 (also referred to as
neuroserpin) may alter neural signaling as its overexpression
significantly influences the levels of a major postsynaptic
scaffolding protein, postsynaptic density protein 95 (Tsang et al.,
2014), and affects the density and shape of dendritic spines
(Borges et al., 2010) and neurite outgrowth (Parmar et al., 2002;
Navarro-Yubero et al., 2004; Lee et al., 2012). An increase in
Serpini1 has been shown to increase the density of dendritic
protusions (Borges et al., 2010). Accordingly, our findings that
COA decreased both miR-27a and Serpini1 protein aligns with
previously observed decreases in PFC cortex spine density
following COA (Robinson et al., 2002). Altered synaptic profile
in the PFC may influence the cognitive/associated role that plays
a factor in the development of tolerance (Tiffany et al., 1991;
Cox and Tiffany, 1997; Mitchell et al., 2000; Miguez et al., 2014).
Interestingly, a lower baseline level of miR-27a was observed in
B6 vs. D2 animals (Supplementary Figure 1), which may explain
the lower sensitivity of B6 to the analgesic effects of morphine
(i.e., B6 ED90 is 31.2 mg/kg while D2 ED90 is 7.7 mg/kg).
Similar neuroadaptive roles can be inferred from the miRNAs
confirmed by qRT-PCR. In particular, miR-483 presents an
interesting link between our mRNA findings and current miRNA
results. MiR-483 resides in the second intron of imprinted
Igf2 and is known to be a regulatory factor for Igf2/H19
expression (Veronese et al., 2010; Ma et al., 2011; miR-
483 overexpression increases Igf2). In our previous study,
high H19 expression was predictive of tolerance development
and H19 expression decreased in the genotypes that became
tolerant to morphine and increased in those that did not.
Thus, an increase in miR-483 (as observed in present study)
would be expected to down-regulate Igf2/H19 expression
consistent with the direction seen in the development of
tolerance.
MiR-505, -146b, and -202 are proposed to be involved in
various adaptive processes such as angiogenesis (miR-505; Yang
et al., 2014), dendritic cell apoptosis and cytokine production
(146b; Park et al., 2015) and cell proliferation (Zhang et al.,
2014). MiR-9 was found to be overexpressed following COA and
specifically by miR-27a (Figure 5). MiR-9 is highly expressed in
the nervous system and plays essential roles in neurogenesis,
axon growth, dendritic development and regulation of the
gene silencing transcription factor REST [repressor element 1
silencing transcription factor]/NRSF (neuron-restrictive silencer
factor) that represses a large array of coding and noncoding
neuron-specific genes important to synaptic plasticity (Giusti
et al., 2014; Wang et al., 2016). MiR-9 has also been
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FIGURE 7 | Chronic morphine down-regulates Serpini1 in prefrontal
cortex of B6 animals. Top panel, representative western blot from 4 to 8
independent animals. Bottom panel, quantification of relative Serpini1 protein
levels was calculated from Serpini1-to-actin densitometric ratios. Data are
presented as the mean ± SEM from 4 saline-treated and 4 morphine-treated
animals. *Significantly different from saline-treated animals using a Student t
test, P < 0.05.
FIGURE 8 | Tolerance to the analgesic effects of morphine in B6 (WT)
and Serpini KO mice. When the 42.0 mg/kg (s.c.) morphine is given once
every other day for a total of 3 injections B6 develop tolerance [decrease in the
% maximal possible effect (%MPE)] at a faster rate than Serpini KO mice
(mean ± SE; n = 8 and 6, KO and B6, respectively). *Significantly different
from WT mice, P < 0.05.
implicated in regulation of the dynorphin κ-opioid receptor
system via down-regulation of REST (Henriksson et al., 2014).
Increased miR-9 would down-regulate REST and result in a net
increase in prodynorphin expression, a result consistent with
some morphine dosing patterns in a region specific manner
(Przewłocka et al., 1996; Király et al., 2006). Overall, it will be
important for future studies to consider the interplay between
various candidate miRNA and characterize their time-course as
it relates to the development of morphine tolerance.
Overall, our results demonstrate for the first time the in vivo
role of Dicer1 in the development of tolerance. Furthermore,
we identified a significant alteration in miRNA expression that
may play a significant regulatory role in the development of
analgesic tolerance to morphine. The miRNA expression data
generated in this study can serve as a future resource to elucidate
mechanisms involved in morphine tolerance. In particular, a
specific role for miR27a and Serpini1 in the behavioral response
to COA is proposed and suggest that a larger role for differential
miRNA expression and mRNA targeting may underlie the
neuroadaptations that mediate tolerance to the analgesic effects
of morphine.
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